Clinical Trials Logo

Filter by:
NCT ID: NCT00643292 Completed - Acute Otitis Media Clinical Trials

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

Start date: January 2003
Phase: Phase 3
Study type: Interventional

A phase 3 randomized, multicenter, double blind, double dummy study to assess the efficacy, safety, and compliance of a single dose of azithromycin extended release compared with a 10-day course of amoxicillin/clavulanate twice daily in children at high risk for persistent or recurrent ear infections

NCT ID: NCT00643201 Completed - Venous Thrombosis Clinical Trials

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Start date: July 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)

NCT ID: NCT00641745 Completed - Schizophrenia Clinical Trials

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Start date: March 2008
Phase: Phase 3
Study type: Interventional

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.

NCT ID: NCT00634049 Completed - Aspergillosis Clinical Trials

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

VITAL
Start date: April 22, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal disease caused by rare fungi.

NCT ID: NCT00633893 Completed - Venous Thrombosis Clinical Trials

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)

NCT ID: NCT00631371 Completed - Clinical trials for Renal Cell Carcinoma

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

INTORACT
Start date: April 2008
Phase: Phase 3
Study type: Interventional

Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.

NCT ID: NCT00630110 Completed - Cancer Clinical Trials

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Start date: February 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.

NCT ID: NCT00629551 Completed - Clinical trials for Depressive Disorder, Major

An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

COMPASS
Start date: February 2008
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in patients with major depressive disorder. The study also includes a double-placebo group (saredutant placebo in combination with paroxetine placebo).

NCT ID: NCT00628095 Completed - Clinical trials for Arthritis, Rheumatoid

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Start date: April 7, 2008
Phase: Phase 2
Study type: Interventional

CE-224,535 is known to block a chemical that acts as a gateway to some of your immune cells. Blocking this gateway prevents the cells from pushing out 2 chemicals called IL-1 and IL-18 that are known to cause some of the inflammation seen in rheumatoid arthritis. It is hoped that taking this drug will reduce the symptoms of rheumatoid arthritis

NCT ID: NCT00626912 Completed - Clinical trials for Subarachnoid Hemorrhage

PRET: Patients Prone to Recurrence After Endovascular Treatment

PRET
Start date: June 2007
Phase: Phase 4
Study type: Interventional

The PRET study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. The first type made of platinum has been used for more than 15 years. The other, referred to as hydrocoil, containing in addition to platinum a polymer layer that expands when in contact with blood, has been in use since 2002. The hypothesis of the PRET study is that the newer hydrocoil will be more effective and yet as safe as the older platinum coil.